This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliographien
Addor, F (2004): „Parallelimporte patentierter Waren: Eine unendliche Geschichte?“ Speaking notes, press seminar „Parallelimporte Patentgeschützter Medikamente“, Berne, June 29th, 2004
Binder T. (2007): Pharmamarkt Schweiz 2006, IMS Health GmbH, Hergiswil http://www.ihaims.ch/Uploads/N274.pdf
Bouvy. F (2003): Overview of pricing and reimbursement measures taken since January 1993, European Federation of Pharmaceutical Industry Associations (EFPIA), Brussels
Bouvy. F (2003): Reference Price Systems, an overview, Federation of Pharmaceutical Industry Associations (EFPIA), Brussels
Bundesamt für Gesundheit (2001): Die Obligatorische Krankenversicherung kurz erklärt, Berne
Bundesministerium für Justiz: Sozialgesetzbuch — Fünftes Buch (V) — Gesetzliche Krankenversicherung (Artikel 1 des Gesetzes v. 20. Dezember 1988, BGB1. I S. 2477), http://bundesrecht.juris.de/sgb_5/, accessed on 20.02.2006
Cambridge Pharma Consulting (2002): Delays in Market Access, Cambridge, UK
College Tarieven Gezondheidszorg: Tariefbeschikking, www.ctg-zaio.nl, accessed on 13.02.2006
Danzon, P. (1997): Pharmaceutical Price Regulation, National Policies versus Global Interests, Washington
Danzon, P. (2001): Reference Pricing Theory and Evidence, Wharton School, University of Pennsylvania, Philadelphia
Department of Health (2006): 2005 Consultation Document Arrangements for the Provision of Dressings, Incontinence Appliances, Stoma Appliances, Chemical Reagents and Other Appliances to Primary and Secondary Care, London
DiMasi. J, (2002): Price trends for prescription pharmaceuticals: 1995–1999, a background report for the department of health and human services, http://aspe.hhs.gov/health/reports/Drug-papers/dimassi/dimasi-final.htm, accessed on 13.02.2006
DiMasi, J. (2004): The economics of follow-on drug research and development, Pharmacoeconomics 2004; 22Suppl. 2: 1–14
DiMasi, J et al. (2003): The price of innovation: New estimates of drug developing costs, J. of Health Economics, 22 (2003) 151–185
Eidgenössisches Volkswirtschaftsdepartement (2000): Parallelimporte und Patentrecht. Bericht des Bundesrates vom 8. Mai 2002 in Beantwortung der Anfrage der Kommission für Wirtschaft und Aufgaben des Nationalrates (WAK) vom 24. Januar 2000
European Commission (1982): European Commission Communication AB1 Nr. C 115, 06.05.1982
European Court of Justice (1974): Judgement of the Court In Case 15/74, between Centrafarm BV et Adriaan de Peijper v Sterling Drug Inc.
European Court of Justice (1998): Judgement of the Court In Case C-355/96, between Silhouette International Schmied GmbH & Co. KG
European Court of Justice (1999): Judgement of the Court in Case C-173/98, between Sebago Inc. and Ancienne Maison Dubois et Fils SA and GB-Unic SA
European Court of Justice (2001): Judgement of the Court in Case 15/01, between Paranova Läkemedel et al. vs. Läkemedelsverket
European Court of Justice (2002): Opinion of Advocate General Léger in Case C-438/02, between Åklagaren v Krister Hanner
European Court of Justice (2004): Judgement of the Court in joined Cases C-2/01 P and C-3/01, between Bundesverband der Arzneimittel-Importeure eV et al. and Bayer AG et al.
European Court of Justice (2006): Judgment of the Court of First Instance in Case T-168/01, between GlaxoSmithKline Services Unlimited and the Commission of European Communities et al.
European Federation of Pharmaceutical Industries Association, EFPIA (2006): The Pharmaceutical Industry in Figures, 2006 Edition, Brussels
Frank R.G., Salkever D.S. (1997): Generic Entry and the Pricing of Pharmaceuticals, J. of Econ & Management Strategy, Spring, S. 75–90
Gansladt M, Maskus K (2001): Parallel Imports of Pharmaceuticals in the European Union, Working Paper No 546, 2001, The Research Institute of Industrial Economics, Stockholm
Ganslandt M., Maskus K.E. (2004): Parallel Imports of Pharmaceuticals in the European Union, J. of Health Economics 23 (2004) 1035–1057
Glenngård A. et al. (2005): Health Systems in Transition: Sweden, Vol. 7 No. 4, Page 48, European Observatory on Health Systems and Policies, Copenhagen
Glynn D. et al. (1997): Survey of parallel trade, National Economic Research Associates NERA, London
Haigh, J. (2003): Parallel Trade in Europe, Strategies for Global Corporations, IMS Health, London
Huskamp, A et al. (2003): The Effect of Incentive-Based Formularies on Prescription-Drug Utilisation and Spending, N Engl. J Med 2003;349: 2224–2232.
Roth Johnsen J. (2006): Health Systems in Transition: Norway, Vol. 8 No. 1 2006, The European Observatory on Health Systems and Policies, Copenhagen, Denmark
IMS Consulting (2003): A comparison of pharmaceutical pricing in Switzerland with selected reference countries, London
Infras/Basys (2002): Auswirkungen staatlicher Eingriffe auf das Preisniveau im Bereich Humanarzneimittel, Bericht im Auftrag des Bundesrates
International Trade Administration, U.S. Department of Commerce (2004): Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation, http://www.ita.doc.gov/td/health/DrugPricingStudy.pdf
Interpharma (2006): Pharmamarkt Schweiz, Ausgabe 2005, Basel
IMS Health (2006): Pricing and Market Access Review 2005, Cambridge, UK
IPSE: Parallel-und Reimporte von Arzneimitteln, Rechtliche Rahmenbedingungen in der Bundesrepublik Deutschland
Kanavos P. and Costa-Font J (2005): Pharmaceutical parallel trade in Europe: stakeholder and competition effects, Economic Policy October 2005, p 778
Knox, D, Richardson, M. (2002): Trade policy and parallel imports, European Journal of Political Economy Vol 19 (2002) 133–151, University of Otago, Dunedin, New Zealand
Läkemedelindustrieföreningen, LIF (2006): FAKTA 2006, Pharmaceutical Market and Health Care, Stockholm
Legemiddelindustrieforenigen, LMI (2002): Facts and Figures 2006: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/FullStory.aspx?m=146
Legemiddelindustrieforenigen, LMI (2006): Facts and Figures 2006: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/tf/2006/files/english/facts_and_figures_2006. pdf
Legemiddelindustrieforenigen, LMI (2007): Facts and Figures 2007: Medicines and Healthcare, Oslo, Norway, http://www.lmi.no/tf/2007/english/facts_and_figures_2007.pdf
Larsson. P (1999): Parallel Imports — Effects of the Silhouette Ruling, The Swedish Competition Authority, Stockholm
Maskus, K. E (2002): Vertical price control and parallel imports: theory and evidence, Washington D.C., The World Bank Group
Mepha Pharma AG (2005): Präsentation zur Jahres-Medienkonferenz, 03.02.2005
Mepha Pharma AG (2007): Präsentation zur Jahres-Medienkonferenz der Mepha-Gruppe, 19.01.2007
Morten Dalelen D. et al. (2006): Dag Morten Dalen et al. (2006), Price regulation and generic competition in the pharmaceutical market, University of Oslo, Health Economics Research Programme, Working Paper 2006.1
El Mundo (2005): Sanidad rebaja el precio de unos 4.500 medicamentos, 01.03.2005, http://www.el-mundo.es/elmundosalud/2005/03/01/industria/1109675885.html, accessed 20.02.2006
Nguyen, N (1997): Physician behavioural response to a Medicare price reduction, Health Service Research
Pedersen K. et al. (2006): The economic impact of parallel import of pharmaceuticals, University of Southern Denmark, Odense
Poget, C. (2005): Are interventions in pharmaceutical markets an effective tool for cost containment? WWZ-Forschungsbericht, Basel
Reiffen D. and Ward M. (2002): Generic Drug Industry Dynamics, The Federal Trade Commission, Washington
Roth Johnsen J. (2006): Health Systems in Transition: Norway, Vol. 8 No. 1 2006, The European Observatory on Health Systems and Policies, Copenhagen, Denmark
Seydoux, Y (2005): Die schweizerische Bevölkerung bezahlt zu viel für Medikamente, Press Statement, Santésuisse, Solothurn
Swiss Federal Statistics Office (2005): Kosten und Finanzierung des Gesundheitswesens 2003, Neuchâtel
West P, Mahon. J (2002): Benefits to patients and payers from parallel trade, The York Health Economic Consortium
Vallgårda S. et al. (2001): Healthcare Systems in Transition: Denmark, Vol. 8, Nr. 7, The World Health Organization Regional Office for Europe, Copenhagen
Vaterlaus, S (2004): Auswirkungen eines Wechsels zur regionalen Erschöpfung im Patentrecht Aktualisierung und Ergänzung des Berichts «Erschöpfung von Eigentumsrechten: Auswirkungen eines Systemwechsels auf die schweizerische Volkswirtschaft», Plaut Economics, Berne
Vaterlaus, S (2002): Erschöpfung von Eigentumsrechten: Auswirkungen eines Systemwechsels auf die schweizerische Volkswirtschaft, Plaut Economics, Berne, Frontier Economics, London
Vaterlaus, S (2004): Warum erodieren Parallelimporte die Preisinsel Schweiz nicht stärker? Ermittlung der Rolle der geistigen Schutzrechte anhand exploratorischer Expertengespräche, Plaut Economies, Berne
VFA (2004): Reimporte: Kostendämpfung auf dem Irrweg, http://vfa.de/de/politik/artikelpo/reimporte.html, acceeded on 15.02.2006
Woodfield, A. (1999): Augmenting Reference Pricing of Pharmaceuticals with strategic cross-product agreements, University of Canterbury Working Paper, Christchurch, New Zealand
World Health Organization, (2002): Healthcare Systems in Transition: Switzerland, The World Health Organization, Copenhagen
World Trade Organisation: Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag AG
About this chapter
Cite this chapter
(2008). Quellenverzeichnis. In: Parallelimporte von Arzneimitteln. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8587-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8587-3_7
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8586-6
Online ISBN: 978-3-7643-8587-3
eBook Packages: Life Science and Basic Disciplines (German Language)